NCM · Biotechnology

Relmada Therapeutics, Inc. (RLMD) Stock

$3.39 +6.94% NCM: RLMD Healthcare

Valuation

MetricValue
Price$3.39
Market Cap$355.58M
P/E Ratio-3.91
P/B Ratio1.96
P/S Ratio0.00
EPS (TTM)$-1.45
52-Week High$8.00
52-Week Low$1.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.52%
ROA-28.27%
ROCE-30.78%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio15.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-126.0M$-161.0M$-104.0M$-84.0M$-59.0M
Net Profit$-126.0M$-157.0M$-99.0M$-80.0M$-57.0M
EPS$-7.16$-5.30$-3.28$-2.65$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$223.0M$153.0M$98.0M$46.0M$94.0M
Total Liabilities$15.0M$12.0M$12.0M$10.0M$7.0M
Cash$44.0M$5.0M$4.0M$4.0M$3.0M
Borrowings$0$0$0$0$0

Latest News

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 GlobeNewswire · Jul 16, 2026 Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes MT Newswires · Jun 29, 2026 Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes GlobeNewswire · Jun 29, 2026 Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now Insider Monkey · Jun 19, 2026 HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target MT Newswires · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-92.0M$-104.0M$-52.0M$-52.0M$-46.0M
Investing Cash Flow$-54.0M$20.0M$50.0M$52.0M$-48.0M
Financing Cash Flow$3.0M$2.0M$0$0$0
Net Cash Flow$42.0M$-39.0M$-1.0M$0$0
Free Cash Flow$-92.0M$-104.0M$-52.0M$-52.0M$-46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA-5.91
FCF Yield-12.18%
Quick Ratio29.52
Interest Coverage0.00
Return 1Y623.23%
Return 3Y83.10%
Return 5Y-80.32%

Ownership

Insiders Held2.90%
Institutions Held91.38%
Institutions Float Held94.11%
Institutional HolderSharesReport Date
Squadron Capital Management LLC8,474,5712026-03-31
Spruce Street Capital LP6,262,1142026-03-31
Venrock Adviser, LLC4,843,3802026-03-31
Adage Capital Partners GP L.L.C.4,763,1582026-03-31
Orbimed Advisors LLC.4,715,8642026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACETAdicet Bio, Inc. $5.61 -2.26% -0.57 $52.44M 0.00%
ACRVAcrivon Therapeutics, Inc. $1.91 +2.14% -1.12 $81.75M 0.00%
CBUSCibus, Inc. $1.55 -2.52% -1.04 $118.31M 0.00%
FBIOFortress Biotech, Inc. $2.13 +2.15% 0.64 $70.92M 0.00%
IMUXImmunic, Inc. $8.19 +8.33% -1.59 $111.56M 0.00%

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. is led by CEO Sergio Traversa, publicly traded since 2014.

Relmada Therapeutics, Inc. (RLMD) stock trades at $3.39 with a market capitalization of $355.58M. The stock is valued at a price-to-earnings (P/E) ratio of -3.91, price-to-book of 1.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.80 and $8.00, and currently trades 57.6% below its 52-week high.

On profitability, Relmada Therapeutics, Inc. generates a return on equity (ROE) of -47.52%, return on capital employed of -30.78%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides